Exendin-4 promotes actin cytoskeleton rearrangement and protects cells from Nogo-A-Δ20 mediated spreading inhibition and growth cone collapse by down-regulating RhoA expression and activation via the PI3K pathway

Publication date: January 2019Source: Biomedicine & Pharmacotherapy, Volume 109Author(s): Fei Zhao, jianwei Li, Renjie Wang, Huiyou Xu, Ke Ma, Xianbin Kong, Zhonglei Sun, Xuegang Niu, Jipeng Jiang, Baohu Liu, Bo Li, Feng Duan, Xuyi ChenAbstractExendin-4 is a protein of the GLP-1 family currently used to treat diabetes. Recently, a greater number of biological properties have been associated with the GLP-1 family. Our data shows that exendin-4 treatment significantly increases the cytoskeleton rearrangement, which leads to an increasingly differentiated phenotype and reduced cell migration. We also found that exendin-4 could prevent SH-SY5Y and PC12 cells from Nogo-A-Δ20 mediated spreading inhibition and neurite collapse. Western blot analysis indicated that exendin-4 treatment both reduced the expression and activation of RhoA via the PI3K signaling pathway. These data suggest that exendin-4 may protect nerve regeneration by preventing the inhibition of Nogo-A via down-regulating RhoA expression and activation.

Source: Biomedicine and Pharmacotherapy - November 3, 2018 Category: Drugs & Pharmacology Source Type: research